Information de reference pour ce titreAccession Number: | 00005407-201601120-00021.
|
Author: | Wald, Arnold MD 1
|
Institution: | (1)Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health, Madison
|
Title: | |
Source: | JAMA. 315(2):185-191, January 12, 2016.
|
Abstract: | Importance: Chronic constipation accounts for at least 8 million annual visits to health care providers in the United States and is associated with large expenditures for diagnostic testing and prescription and nonprescription laxatives.
Observations: Strong evidence for efficacy has been established for stimulant and osmotic laxatives, new intestinal secretogogues, and peripherally restricted [mu]-opiate receptor antagonists, the latter a major advance in the treatment of opioid-induced constipation (OIC). An algorithm provided to evaluate chronic idiopathic constipation (CIC) that is refractory to available laxatives focuses on the importance of defecation disorders and biofeedback therapies. When used appropriately, available stimulant laxatives such as senna and bisacodyl are both safe and effective when used long-term. There is a paucity of (and a strong desire for) studies that compare inexpensive laxatives with newer agents that work by other mechanisms.
Conclusions and Relevance: The choice of treatment for CIC and OIC should be based on cost as well as efficacy. The small subgroup of patients who do not respond to currently available laxatives requires further evaluation at experienced centers that are capable of performing studies of defecation and colonic transit.
Copyright 2016 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.
|
References: | 1. Shah ND, Chitkara DK, Locke GR, Meek PD, Talley NJ. Ambulatory care for constipation in the United States, 1993-2004. Am J Gastroenterol. 2008;103(7):1746-1753
2. Bharucha AE, Pemberton JH, Locke GR III. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218-238
3. Ford AC, Moayyedi P, Lacy BE, et al.Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(suppl 1):S2-S26
4. Wong RK, Palsson OS, Turner MJ, et al.. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105(10):2228-2234
5. Heidelbaugh JJ, Stelwagon M, Miller SA, Shea EP, Chey WD. The spectrum of constipation-predominant IBS and CIC: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110:580-587
6. Naloxegol (Movantik) for opioid-induced constipation. Med Lett Drugs Ther. 2015;57(1478):135-137
7. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608
8. Balshem H, Helfand M, Schunemann HJ, et al.. GRADE guidelines: 3: rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-406
9. Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag, or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014;39(3):239-253
10. Yiannakou Y, Piessevaux H, Bouchoucha M, et al.. A randomized, double blind, placebo controlled, phase 3 trial to evaluate the efficacy, safety and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110(5):741-748
11. Cinca R, Chera D, Gruss HJ, Halphen M. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation-a comparison in a controlled environment. Aliment Pharmacol Ther. 2013;37(9):876-886
12. Ford AC. Death knell for placebo-controlled trials in chronic idiopathic constipation? Gastroenterology. 2013;145(4):897-898
13. Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55(4):1090-1097
14. Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci. 2011;56(6):1619-1625
15. Lembo AJ, Schneier HA, Shiff SJ, et al.. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527-536
16. Atluri DK, Chandar AK, Bharucha AE, Falck-Ytter Y. Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. Neurogastroenterol Motil. 2014;26(4):499-509
17. Shailubhai K, Comiskey S, Foss JA, et al.. Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses. Dig Dis Sci. 2013;58(9):2580-2586
18. Quigley EM. Open channels for functional bowel disorders: guanylate cyclase C agonists in IBS and CC. Dig Dis Sci. 2013;58(9):2446-2448
19. Mueller-Lissner S, Kamm MA, Wald A, et al.. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897-903
20. Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol. 2011;9(7):577-583
21. Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100(1):232-242
22. Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36(5):386-389
23. Nelson AD, Camilleri M. Chronic opioid-induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015;8(4):206-220
24. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396
25. Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate-induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997;37(10):904-907
26. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(10):1566-1574
27. Cryer B, Katz S, Vallejo R, Popescu A, Ueno R. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2014;15(11):1825-1834
28. Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain. Am J Gastroenterol. 2015;110(5):725-732
29. Leppert W. Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. Curr Drug Targets. 2014;15(1):124-135
30. US Food and Drug Administration. FDA approves new extended-release oxycodone with abuse-deterrent properties. http://www.fda.gov/NewsEvents/Ne...- ouverture dans une nouvelle fenêtre. Accessed December 18, 2015.
31. Webster L, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain. 2013;154(9):1542-1550
32. Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015;3(5):471-480
33. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: removal of naloxegol from control. Final rule. Fed Regist. 2015;80(15):3468-3470
34. Bharucha AE, Wald AM. Anorectal disorders. Am J Gastroenterol. 2010;105(4):786-794
35. Chiarioni G, Kim SM, Vantini I, Whitehead WE. Validation of the balloon evacuation test: reproducibility and agreement with findings from anorectal manometry and electromyography. Clin Gastroenterol Hepatol. 2014;12(12):2049-2054
36. Rao SS, Valestin J, Brown CK, Zimmerman B, Schulze K. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial. Am J Gastroenterol. 2010;105(4):890-896
37. Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109(8):1141-1157, 1058
|
Language: | English.
|
Document Type: | Review: Review.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0098-7484
|
NLM Journal Code: | 7501160
|
DOI Number: | https://dx.doi.org/10.1001/jama....- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|